CXCR6-transduced T cells for targeted tumor therapy

US11723922B2 · kind B2 · utility

Assignee

• Ludwig-Maximilians-Universitat Munchen · DE

Inventors

• Sebastian Kobold · Munich, DE
• Stefan Endres · Munich, DE
• Moritz RAPP · Schlieren, CH
• Simon Grassmann · Munich, DE

Key dates

• Filing date: Oct 14, 2016
• Grant date: Aug 15, 2023
• Expiry date: Jan 24, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/13043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) γδ T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.